Zobrazeno 81 - 90
of 125
pro vyhledávání: '"Tamas Masszi"'
Autor:
Laimonas Griskevicius, Gianantonio Rosti, Verena S. Hoffmann, Tamas Masszi, Andrija Bogdanovic, Bengt Simonsson, Boris Labar, Josef Thaler, Joelle Guilhot, Sandra Lejniece, Andrey Zaritskey, Jiri Mayer, Richard E. Clark, Irena Preložnik Zupan, Frederiki Melanthiou, Tomasz Sacha, Juan Luis Steegmann, Karel Indrak, Rüdiger Hehlmann, Panagiotis Panagiotidis, Antonio Almeida, Adriana Colita, Irina Dyagil, Witold Prejzner, Fausto Castagnetti, Hele Everaus, Kimmo Porkka, Gabriele Schubert-Fritschle, Susanne Saussele, Joerg Hasford, Anna G. Turkina, Georgi Mihaylov, Doris Lindoerfer, Andrzej Hellmann, Michele Baccarani, Noortje Thielen
Publikováno v:
Blood. 124:3160-3160
Introduction: Most of the knowledge about treatments and outcome of CML patients originates from clinical studies. To get new and unbiased insights in the epidemiology, treatment and outcome of CML, the EUTOS population-based registry of newly diagno
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of
Publikováno v:
Blood. 124:4547-4547
Background: With effective tyrosine kinase inhibitor (TKI) therapy, CML-CP disease burden can be reduced to minimal levels, and pts with CML-CP can have a life expectancy similar to that of the general population. Current guidelines recommend that pt
Autor:
Steven M. Horwitz, Wojciech Jurczak, Tamas Masszi, Andrei R. Shustov, Gajanan Bhat, Dina Ben-Yehuda, Mi Rim Choi, Kerry J. Savage, Achiel Van Hoof, Lee F. Allen, Pier Luigi Zinzani, Sarit Assouline
Publikováno v:
Blood. 124:3075-3075
Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas associated with a poor prognosis for most subtypes. Anthracycline-based therapies such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Francesco Passamonti, Pierre Zachee, Ruben A. Mesa, Simon Durrant, Mark M. Jones, Jean-Jacques Kiladjian, Ulrich Pirron, William M. Garrett, Tomasz Lawniczek, Martin Griesshammer, Srdan Verstovsek, Jingjin Li, Tamas Masszi, Shui He, Claire N. Harrison, Fabrizio Pane, Alessandro M. Vannucchi
Publikováno v:
Journal of Clinical Oncology. 32:7026-7026
7026 Background: PV is a myeloproliferative neoplasm characterized by increased erythrocytosis, disease-related symptom burden (eg, pruritus), and risk of vascular events (thrombosis and/or hemorrh...
Autor:
Gergely Peskó, Zsigmond Jenei, Gergely Varga, Astrid Apor, Hajnalka Vágó, Sándor Czibor, Zoltán Prohászka, Tamás Masszi, Zoltán Pozsonyi
Publikováno v:
Cardiovascular Ultrasound, Vol 17, Iss 1, Pp 1-8 (2019)
Abstract Background Left ventricular hypertrophy and diastolic dysfunction are common echocardiographic features of both aortic valve stenosis (AS) and cardiac amyloidosis (CA). These two different entities therefore may mask each other. From recent
Externí odkaz:
https://doaj.org/article/59ebf78b27cd44b88da0d2843ce158a4
Autor:
Tamas Masszi, Kinga Káel, Imre Bodó, Júlia Galgóczi, Krisztina Szabó, Katalin Pap, János Dolgos, Beata Vilimi, Attila Szederjesi, Péter Farkas, Andrea Várkonyi
Publikováno v:
Blood. 122:3589-3589
Introduction Acquired hemophilia A (AHA) is a rare severe disorder caused by autoantibodies against FVIII resulting in significant morbidity and mortality up to 20 % in some studies. The two pillars of treatment include acute bleeding control, and im
Autor:
Maria Asunción Echeveste, Gert J. Ossenkoppele, Bruno Martino, Laimonas Griskevicius, Michele Baccarani, Johan Richter, Ljubomir Petrov, Gianantonio Rosti, Andreas Hochhaus, Consultant in Hematology, Tim H. Brümmendorf, Michel Tulliez, Jesper Stentoft, Giuseppe Saglio, Philipp le Coutre, Juan Luis Steegmann, Peter Schuld, Angela Pellegrino, Tamas Masszi, Andrzej Hellmann, Claudia Walasek, Delphine Rea, Norbert Gattermann, Francois-Xavier Mahon, Nicholas C.P. Cross
Publikováno v:
Blood. 122:4030-4030
Background Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor (TKI) that has been shown to be more active than imatinib at inducing earlier and deeper molecular responses in the frontline treatment of chronic myeloid leukemia (CML; Larson, et
Autor:
Attila Tordai, Judit Csomor, Tamas Masszi, Botond Timár, Zoltán Mátrai, András Kozma, Hajnalka Andrikovics
Publikováno v:
Blood. 122:5033-5033
Background Myeloid sarcomas are rare extramedullary manifestations of acute myeloid leukemia (AML) representing less then 1% of all cases. Since they invariably progress into systemic disease, early AML-like chemotherapy is mandated. Myeloproliferati